Medigene AG Company Description
Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer.
The company’s end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications.
Its lead product includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications.
The company also develops MDG2011, MDG2021, MDG2012, MDG20XX, and MDG10xx to treat multiple solid tumors.
It has a strategic partnership with BioNTech to develop TCRbased immunotherapies against cancer; and 2seventy bio, Inc. for the development of TCR immunotherapies, as well as a collaboration agreement with National Cancer Institute to evaluate the potential of T cell receptors to be used in new cell constructs for the treatment of solid tumors.
It has operations in Germany, the United States, and Asia. The company has a research collaboration agreement with WuXi Biologics to design and co-research TCR-guided T Cell engagers (TCR-TCEs) for the treatment of difficult-to-treat tumors; and strategic co-development agreement with EpimAb Biotherapeutics, Inc. to research and develop off-the-shelf TCR-guided T Cell Engagers for the treatment of immune-related disorders, such as solid tumors.
Medigene AG was founded in 1994 and is headquartered in Munich, Germany.
| Country | Germany |
| Founded | 1994 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 76 |
| CEO | Selwyn Ho |
Contact Details
Address: Lochhamer Strasse 11 Munich, 82152 Germany | |
| Phone | 49 89 2000 330 |
| Website | medigene.com |
Stock Details
| Ticker Symbol | MDGEF |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | DE000A40ESG2 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Selwyn Ho MB BS, MBBS | Chief Executive Officer and Chairman of Executive Management Board |
| Dr. Dolores J. Schendel | Chief Scientific Officer, Member of Executive Management Board and Head of Research and Development |
| Dr. Ernst-Ludwig Winnacker | Co-Founder and Chairman Scientific Advisory Board |
| Dr. Birger Kohlert | Chief Financial Officer |
| Pamela Keck | Vice President of Investor Relations and Corporate Communications |
| Dr. Kirsty Crame M.D. | Vice President and Head of Clinical Research and Development |